|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: Pseudomonas Aeruginosa Vaccines and Therapeutics
La Merie, June 2010, Pages: 22
The present Competitive Intelligence Report about Pseudomonas aeruginosa Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, peptides and small molecules against infection with Pseudomonas aeruginosa as of June 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Pseudomonas aeruginosa is an opportunistic gram-negative bacteria that lives in soil, water, and even in environments like hot tubs. For most healthy people, this bacteria seldom poses a problem. Pseudomonas aeruginosa is much more dangerous to populations who have weak immune systems, the elderly, and those who have been hospitalized for long periods of time. People with cystic fibrosis and with full-blown AIDS frequently die from infections created by the bacteria. Hospital-acquired pneumonia, particularly ventilator-associated pneumonia , causes considerable morbidity and mortality despite antimicrobial therapy and advances in supportive care. It is the second most frequent nosocomial infection and is the major cause of death among hospital-acquired infections.
At present there is no approved vaccine available for prevention of P. aeruginosa infection. Treatment of P. aeruginosa infection is limited to number of antibiotics. With the advent of biotechnology, a number of experimental vaccines and therapeutic antibodies are being evaluated in preclinical and clinical R&D. Peptide and small molecule therapeutics are being developed to fight bacterial infections including those caused by P. aeruginosa.
The report includes a compilation of currently active projects in development of vaccines, antibodies, peptides and small molecules targeting Pseudomonas aeruginosa for prophylaxis and treatment of P. aeruginosa infection. In addition, the report lists company-specific R&D pipelines of P. aeruginosa Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Antibiotic Resistance 2012: The Antibiotic Development Pipeline and Strategies to Combat Antibiotic Resistance
Competitor Analysis: RSV Vaccines and Therapeutics
Competitor Analysis: Streptococcal Vaccines and Antibodies
Innovations in Combating Infectious Diseases: Opportunities in Therapeutics and Diagnostics through Application of Proteomics, Genomics, Nanotechnology, and Novel Sources of Lead Generation
Competitor Analysis: Anthrax Vaccines and Therapeutics
Competitor Analysis: Cytomegalovirus (CMV) Vaccines and Therapeutics
Hospital Acquired Bacterial Infections Market to 2016 - Increasing Antibiotic Resistance and Increasing Population of Critically Ill Patients To Drive Growth
Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical
Antibiotics and Drug Resistance 2008
Competitor Analysis: Anti-Infective Antibodies
|
|
|
|
